Simultaneous use of Tumor Necrosis Factor, Lipid Profile, and ß-hCG As Markers of Severity of Preeclampsia.

Objective: Tumor necrosis factor, Lipid Profile, and ß-hCG are markers that proved to be changed with preeclampsia. We aim to study their combined use as predictors of the severity of preeclampsia. Methods: A case-control study was conducted in our University Hospitals on pregnant women complicated by mild or severe PE and healthy normal pregnant women as a control group. Samples of these markers were taken at a gestational age between 28 and 36 weeks. Results: A total number of 90 pregnant women were selected. The first group was mild PE (17 cases), the second group was severe PE (28 cases), and the third group was normal pregnant women (control group 45 cases). There is a statistically significant positive correlation between ß-hCG, triglycerides, Cholesterol, LDL, VLDL, and Tumor necrosis factor. These markers correlate with the severity of PE. HDL demonstrates a statistically significant negative correlation with TNF-α and ß-hCG. Conclusions: There is a strong correlation between the increase of TNF, ß-hCG, triglycerides, LDL, and cholesterol in cases of PE. These markers are associated with the severity of PE. These markers can be incorporated into a predictive model for PE.

Laparoscopic ovarian drilling before IVF/ICSI in polycystic ovarian syndrome patients with high antimullarian hormone.

OBJECTIVE: To evaluate the effect of performing laparoscopic ovarian drilling [LOD] before proceeding to in vitro fertilization [IVF] or intracytoplasmic sperm injection [ICSI] on the cycle outcomes in polycystic ovarian syndrome [PCOS] patients with high antimullerian hormone [AMH] levels. STUDY DESIGN: A retrospective case-control study. PATIENTS AND METHODS: The study was conducted in the Fertility Care Unit in our University Hospital. The participants of the study were PCOS women with high serum AMH levels [≥ 7 ng/ml] who were subjected to IVF/ICSI. Women who underwent LOD in the preceding 3 months before IVF/ICSI [study group; n = 76] were compared with a control group of women who did not undergo LOD [control group; n = 71]. RESULTS: Total gonadotropin consumption and the number of stimulation days were significantly lower with LOD [P = 0.026 and 0.010, respectively]. Oocyte maturity rate was significantly higher with LOD [P = 0.028]. The incidence of severe OHSS was significantly lower with LOD [P = 0.026]. No significant difference between both groups in the pregnancy and implantation rates. CONCLUSION: The LOD before IVF/ICSI in PCOS patients with high AMH [≥ 7 ng/ml] has the benefits of reduction in gonadotropins consumption and stimulation days with an increase in the percentage of collected mature oocytes and decrease in the incidence of severe OHSS; however, it seems not to improve the pregnancy and implantation rates.

Can Ki67 and Caspase Predict Molar Progression?

Background: A clinical risk score has been introduced into the management of persistent trophoblastic disease to allow individualized therapy. However, this risk scoring system lacks histopathologic predictors. The hypothesis is that there are prognostic histological markers that might contribute to the detection of those cases that will have persistent trophoblastic disease. Methods: Trophoblastic proliferation and apoptosis were investigated via immunohistochemical expression of Ki67 and caspase in 24 complete moles. These were divided into two groups; group A represented cases with persistent trophoblastic disease and group B represented cases with no persistent trophoblastic disease. Sections were immunostained with a monoclonal antibody for both caspase and Ki67. Results: No statistically significant difference was found between either group regarding the expression of Ki67 or caspase. Conclusion: Neither proliferation or apoptosis are reliable markers for progression of molar pregnancy.

Timing of initiation of low-molecular-weight heparin administration in pregnant women with antiphospholipid syndrome: a randomized clinical trial of efficacy and safety.

OBJECTIVE: We aimed to evaluate the effect of different timing of initiation of low-molecular-weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS). MATERIALS AND METHODS: A randomized controlled study was conducted on women with obstetrical APS. All participants were randomly divided at documentation of positive pregnancy test into two groups; early initiation group in which LMWH therapy was started once positive pregnancy test was established (in the fifth week of gestation), and later initiation group in which LMWH therapy was started after sonographic confirmation of fetal cardiac pulsation (in the seventh week of gestation). In both groups, LMWH (enoxaparin) was given at a dose of 40 mg/day subcutaneously and the therapy continued until end of pregnancy. The primary outcome measure was ongoing pregnancy rate and the secondary outcome measures were fetal loss, live birth rate, preterm labor before 34 weeks of gestation, intrauterine growth restriction (IUGR), and congenital fetal malformations. RESULTS: Ninety-four women (48 in the early initiation group and 46 in the later initiation group) were subjected to final analysis. The ongoing pregnancy rate was significantly higher in the early initiation group than in the later initiation group (81.2% vs 60.9%; P=0.040). However, both groups were similar in the incidences of fetal loss, preterm labor before 34 weeks of gestation, and IUGR, and live birth rate. No recorded congenital fetal malformations in both groups. CONCLUSION: Early administration of LMWH for pregnant women with obstetrical APS reduces early pregnancy loss, but does not affect the incidence of late obstetrical complications.

Use of sildenafil citrate in cases of intrauterine growth restriction (IUGR); a prospective trial.

OBJECTIVE: Intrauterine growth restriction (IUGR) is one of the most serious complications of pregnancy. Up to date, there is no evidence of achieving antenatal treatment of IUGR with abnormal placentation. Although, Sildenafil citrate has shown promising results, there are no firm conclusion till now. The aim of our study is to evaluate the use of Sildenafil citrate in the treatment of IUGR cases associated with impaired placental circulation. MATERIALS AND METHODS: This was a prospective non-randomized study conducted at Mansoura university hospitals starting from March 2016 till October 2017. The studied population included singleton pregnancy and suffering from IUGR associated with impaired placental circulation. RESULTS: This study included 50 pregnant women. Cases were divided into two groups. The first group received sildenafil citrate and the second control group did not receive sildenafil citrate. After 4 weeks after the 1st dose of Sildenafil significant decrease in umbilical artery Doppler indices. There was a statistically significant difference in the mean birth weight at delivery and neonatal admission to the newborn nursery in sildenafil group. CONCLUSION: sildenafil citrate treatment may present a new hope towards better perinatal outcomes for pregnancies complicated by IUGR and impaired placental circulation that may help to decrease neonatal admission to the newborn nursery.